Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1997 May;150(5):1531–1536.

Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide.

S Webster 1, B Bonnell 1, J Rogers 1
PMCID: PMC1858209  PMID: 9137079

Abstract

Activation of the classical pathway in Alzheimer's disease derives from the binding of the first protein, subcomponent C1q, to the amyloid beta-peptide (A beta). Analysis of the binding of C1q to A beta by competitive enzyme-linked immunosorbent assay shows that A beta fragments 1-16 and 1-28 but not 12-28 and 17-42 are capable of inhibiting the A beta/C1q interaction, implicating the A beta 1-11 region as the C1q binding site. Binding is also shown to be inhibited by conditions of high ionic strength, suggesting that charged side chains in the A beta 1-11 region are critical to the A beta/c1q interaction. Ultrastructural evidence of binding is provided by platinum replica electron microscopy. Along with a previous demonstration of the 14-26 region of the C1q A chain as the A beta binding site, these findings suggest that attractions between a negative charge cluster in A beta 1-11 and a positive charge cluster in C1qA14-26 mediate the binding of A beta and C1q.

Full text

PDF
1531

Images in this article

1533Figure 1
on p.1533

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama H., McGeer P. L. Brain microglia constitutively express beta-2 integrins. J Neuroimmunol. 1990 Nov;30(1):81–93. doi: 10.1016/0165-5728(90)90055-r. [DOI] [PubMed] [Google Scholar]
  2. Cooper N. R. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol. 1985;37:151–216. doi: 10.1016/s0065-2776(08)60340-5. [DOI] [PubMed] [Google Scholar]
  3. Davis J. B., McMurray H. F., Schubert D. The amyloid beta-protein of Alzheimer's disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun. 1992 Dec 15;189(2):1096–1100. doi: 10.1016/0006-291x(92)92317-q. [DOI] [PubMed] [Google Scholar]
  4. Eikelenboom P., Hack C. E., Rozemuller J. M., Stam F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):259–262. doi: 10.1007/BF02890024. [DOI] [PubMed] [Google Scholar]
  5. Eikelenboom P., Rozemuller J. M., Kraal G., Stam F. C., McBride P. A., Bruce M. E., Fraser H. Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60(5):329–336. doi: 10.1007/BF02899564. [DOI] [PubMed] [Google Scholar]
  6. Eikelenboom P., Stam F. C. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;47(1):17–25. doi: 10.1007/BF02890185. [DOI] [PubMed] [Google Scholar]
  7. Eikelenboom P., Stam F. C. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 1982;57(2-3):239–242. doi: 10.1007/BF00685397. [DOI] [PubMed] [Google Scholar]
  8. Eikelenboom P., Zhan S. S., Kamphorst W., van der Valk P., Rozemuller J. M. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer's disease. Virchows Arch. 1994;424(4):421–427. doi: 10.1007/BF00190565. [DOI] [PubMed] [Google Scholar]
  9. Haga S., Ikeda K., Sato M., Ishii T. Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 1993 Jan 22;601(1-2):88–94. doi: 10.1016/0006-8993(93)91698-r. [DOI] [PubMed] [Google Scholar]
  10. Halverson K., Fraser P. E., Kirschner D. A., Lansbury P. T., Jr Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry. 1990 Mar 20;29(11):2639–2644. doi: 10.1021/bi00463a003. [DOI] [PubMed] [Google Scholar]
  11. Hilbich C., Kisters-Woike B., Reed J., Masters C. L., Beyreuther K. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J Mol Biol. 1991 Mar 5;218(1):149–163. doi: 10.1016/0022-2836(91)90881-6. [DOI] [PubMed] [Google Scholar]
  12. Jiang H., Burdick D., Glabe C. G., Cotman C. W., Tenner A. J. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol. 1994 May 15;152(10):5050–5059. [PubMed] [Google Scholar]
  13. Joachim C. L., Selkoe D. J. The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis Assoc Disord. 1992 Spring;6(1):7–34. doi: 10.1097/00002093-199205000-00003. [DOI] [PubMed] [Google Scholar]
  14. Klegeris A., Walker D. G., McGeer P. L. Activation of macrophages by Alzheimer beta amyloid peptide. Biochem Biophys Res Commun. 1994 Mar 15;199(2):984–991. doi: 10.1006/bbrc.1994.1326. [DOI] [PubMed] [Google Scholar]
  15. Lorenzo A., Yankner B. A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12243–12247. doi: 10.1073/pnas.91.25.12243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mattson M. P., Tomaselli K. J., Rydel R. E. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 1993 Sep 3;621(1):35–49. doi: 10.1016/0006-8993(93)90295-x. [DOI] [PubMed] [Google Scholar]
  17. McGeer P. L., Akiyama H., Itagaki S., McGeer E. G. Immune system response in Alzheimer's disease. Can J Neurol Sci. 1989 Nov;16(4 Suppl):516–527. doi: 10.1017/s0317167100029863. [DOI] [PubMed] [Google Scholar]
  18. Mrak R. E., Sheng J. G., Griffin W. S. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol. 1995 Aug;26(8):816–823. doi: 10.1016/0046-8177(95)90001-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., Cotman C. W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993 Apr;13(4):1676–1687. doi: 10.1523/JNEUROSCI.13-04-01676.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pike C. J., Walencewicz-Wasserman A. J., Kosmoski J., Cribbs D. H., Glabe C. G., Cotman C. W. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem. 1995 Jan;64(1):253–265. doi: 10.1046/j.1471-4159.1995.64010253.x. [DOI] [PubMed] [Google Scholar]
  21. Pike C. J., Walencewicz A. J., Glabe C. G., Cotman C. W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991 Nov 1;563(1-2):311–314. doi: 10.1016/0006-8993(91)91553-d. [DOI] [PubMed] [Google Scholar]
  22. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt B., Ward P. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016–10020. doi: 10.1073/pnas.89.21.10016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rogers J., Webster S., Lue L. F., Brachova L., Civin W. H., Emmerling M., Shivers B., Walker D., McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging. 1996 Sep-Oct;17(5):681–686. doi: 10.1016/0197-4580(96)00115-7. [DOI] [PubMed] [Google Scholar]
  24. Roher A. E., Lowenson J. D., Clarke S., Wolkow C., Wang R., Cotter R. J., Reardon I. M., Zürcher-Neely H. A., Heinrikson R. L., Ball M. J. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem. 1993 Feb 15;268(5):3072–3083. [PubMed] [Google Scholar]
  25. Simmons L. K., May P. C., Tomaselli K. J., Rydel R. E., Fuson K. S., Brigham E. F., Wright S., Lieberburg I., Becker G. W., Brems D. N. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol. 1994 Mar;45(3):373–379. [PubMed] [Google Scholar]
  26. Soreghan B., Kosmoski J., Glabe C. Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. J Biol Chem. 1994 Nov 18;269(46):28551–28554. [PubMed] [Google Scholar]
  27. Ueda K., Fukui Y., Kageyama H. Amyloid beta protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid beta protein. Brain Res. 1994 Mar 14;639(2):240–244. doi: 10.1016/0006-8993(94)91736-1. [DOI] [PubMed] [Google Scholar]
  28. Webster S., Glabe C., Rogers J. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun. 1995 Dec 26;217(3):869–875. doi: 10.1006/bbrc.1995.2852. [DOI] [PubMed] [Google Scholar]
  29. Webster S., O'Barr S., Rogers J. Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J Neurosci Res. 1994 Nov 1;39(4):448–456. doi: 10.1002/jnr.490390412. [DOI] [PubMed] [Google Scholar]
  30. Webster S., Rogers J. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J Neurosci Res. 1996 Oct 1;46(1):58–66. doi: 10.1002/(SICI)1097-4547(19961001)46:1<58::AID-JNR8>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES